Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
VAT GLOW GLOW EUR 120.30 EUR 120.30 0.00 incl
(2025 update) As of April 2025, there is no FDA-approved generic version of semaglutide (the active ingredient in Ozempic and Wegovy) available in the United States
Using the treatment-regimen estimandwhich incorporates treatment discontinuation and certain additional eventsaverage weight loss was: 12.2% with survodutide 3.6 mg 13.0% with survodutide 6 mg 5.4% with placebo A separate efficacy estimand, designed to estimate results had participants remained on treatment without prohibited weight-management therapy, produced weight loss of up to 16.6%
Both medications are injectables and are globally used in treating type 2 diabetes and chronic weight management
This represents a novel area of treatment at the overlap between the inflammatory and metabolic nexus, potentially leading to better outcomes in uncontrolled asthma
